Cure8 research brief
A blood biomarker (OSM) that tracks microscopic inflammation could help detect residual disease activity that fecal calprotectin and routine clinical scores miss. That matters because histological inflammation predicts outcomes and may guide treatment decisions.
Patients with ulcerative colitis, gastroenterology clinicians, IBD researchers, and those interested in biomarkers for disease monitoring.
This journal abstract reports a clinical study of plasma Oncostatin M (OSM) measured alongside fecal calprotectin (FC), CRP, and fibrinogen in 100 patients with ulcerative colitis and 30 healthy controls over two visits (baseline and 12 months).
The authors found that OSM correlated with clinical, endoscopic, and especially histological disease activity, and that OSM added independent, complementary information to FC for predicting histological remission and strict endoscopic remission (MES 0).
OSM appeared most useful for reflecting microscopic (histological) inflammation rather than routine clinical scores or conventional endoscopic thresholds. FC remained the stronger predictor for clinical and endoscopic remission overall, but combining OSM with FC improved discrimination for histological outcomes in their models.
This brief is grounded in the article abstract provided by the journal (structured content depth: abstract). I have not reviewed the full paper beyond the supplied text and do not imply additional results beyond what the abstract reports.
Results are taken from the article abstract (structured content depth: abstract); external validation and full-text review are needed before changing clinical practice.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: INNODOC-MED, award SMIS code 351058
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure...
A wearable sensor that reliably measures inflammation markers (CRP and calprotectin) from sweat could make inflammation monitoring less invasive and more frequent for people with IBD, potentially helping detect flares...
